1. INTRODUCTION
===============

Thyroid cancer is the most common of endocrine malignancy in Canada [@b1-co16-5-23] and the United States [@b2-co16-5-23],[@b3-co16-5-23], with the fastest-rising incidence of all cancers. The estimated number of new cases in Canada in 2008 was 4300, and the deaths attributable to thyroid cancer for 2008 were estimated to have been 180 [@b1-co16-5-23]. In the United States, the incidence is similar [@b3-co16-5-23]. Because thyroid cancer is an indolent disease and because it can recur decades after initial diagnosis and definitive primary treatment, people with a thyroid cancer diagnosis require life-long surveillance and follow-up [@b4-co16-5-23].

Patients with differentiated thyroid carcinoma (papillary and follicular) are usually treated surgically, with near-total or total thyroidectomy, frequently followed by adjuvant radioiodine (^131^I) therapy of thyroid remnants [@b5-co16-5-23]. Traditionally, patients are prepared for radioiodine ablation ([ra]{.smallcaps}) by the withdrawal of thyroid hormone replacement, rendering them hypothyroid. The hypothyroid state increases endogenous levels of thyroid-stimulating hormone ([tsh]{.smallcaps}), which stimulates the uptake of ^131^I in any remaining thyroid cells and often also in differentiated thyroid cancer cells [@b6-co16-5-23]. The induced temporary hypothyroidism can cause substantial morbidities such as cold intolerance, peri-orbital puffiness, weight gain, constipation, and slow movements, negatively affecting quality of life ([qol]{.smallcaps}) [@b7-co16-5-23]. In addition, pre-existing multisystem disorders such as cardiac, renal, and psychiatric diseases may be exacerbated during hypothyroidism.

Although the withdrawal time varies, patients are generally off thyroid replacement hormone for 4--6 weeks; they restart within 1 week after [ra]{.smallcaps}, with thyroid hormone reaching normal levels within 2 months. Some practitioners initially replace the T4 form of hormone with T3, which is more rapidly metabolized, before a short period of total hormone withdrawal, with the intent of shortening the duration of overt hypothyroidism. However, this protocol has been shown to offer no clear benefit [@b8-co16-5-23].

Since the end of the 1990s, several major changes have occurred in the postsurgical management of differentiated thyroid cancers---for example, appreciation of the importance of thyroglobulin (Tg) assays in follow-up, a parallel appreciation of the relative insensitivity of follow-up ^131^I scans [@b9-co16-5-23], and the concurrent development of recombinant humanized [tsh]{.smallcaps} (rh[tsh]{.smallcaps}).

Exogenously administered rh[tsh]{.smallcaps} avoids thyroid hormone withdrawal and was initially approved for use in patients undergoing periodic ^131^I whole-body scans ([wbss]{.smallcaps}) and stimulated Tg measurements during follow-up. With rh[tsh]{.smallcaps}, patients can remain on thyroid replacement, thereby avoiding the associated morbidity of hypothyroidism. Administration of rh[tsh]{.smallcaps} has proved to be a safe and effective method of stimulating ^131^I uptake in patients being monitored for persistent or recurrent thyroid cancer, while maintaining a euthyroid state [@b10-co16-5-23],[@b11-co16-5-23].

In 2006, the American Thyroid Association ([ata]{.smallcaps}) published a guideline on the management of patients with differentiated thyroid cancer. The [ata]{.smallcaps} taskforce issued a level B recommendation for the use of either thyroid hormone withdrawal or rh[tsh]{.smallcaps} for radioiodine remnant ablation [@b12-co16-5-23]. Since then, the European Commission and the U.S. Food and Drug Directorate have both approved the use of rh[tsh]{.smallcaps} for radioiodine remnant ablation in low-risk post-thyroidectomy patients [@b13-co16-5-23],[@b14-co16-5-23].

The efficacy of rh[tsh]{.smallcaps} for diagnostic and surveillance purposes has raised the question of its utility in the preparation of patients for ^131^I adjuvant therapy, stimulating a systematic review of the evidence for the use of rh[tsh]{.smallcaps} for this purpose. Many countries have already approved a role for rh[tsh]{.smallcaps} in therapy of selected low-risk patients, but in some centres, standard practice still limits its use to diagnostic surveillance of previously treated thyroid cancer.

2. METHODS
==========

2.1 Literature Search Strategy
------------------------------

We searched the [medline]{.smallcaps} \[January 1996 through January (week 5) 2008\] and [embase]{.smallcaps} \[1996 through February (week 6) 2008\] databases for relevant evidence. The search terms used included "thyroid cancer," "thyroidectomy," "radioactive iodine ablation," "thyrotropin," and "randomized controlled trials." Relevant articles were selected and reviewed by one reviewer, and the reference lists from those sources were searched for additional trials.

2.2 Inclusion Criteria
----------------------

Articles were selected for inclusion in the systematic review if they were fully published English-language reports, involving human subjects, of randomized controlled trials ([rcts]{.smallcaps}), cohort studies, and retrospective studies comparing [ra]{.smallcaps} preparation using rh[tsh]{.smallcaps} with standard withholding of thyroid hormone therapy in patients with no known metastatic disease. Outcome measures of interest were serum [tsh]{.smallcaps} levels, results of post-therapy scans, iodine biokinetics in remnants, serum Tg, urinary iodine excretion, and [qol]{.smallcaps}.

3. RESULTS
==========

3.1 Literature Search
---------------------

The [medline]{.smallcaps} search yielded 323 results, twenty-two of which were potentially relevant and ordered for full review. The [embase]{.smallcaps} search yielded 132 results, eight of which were potentially relevant and not already included in the [medline]{.smallcaps} search. If several papers were published concerning the same dataset, but with updated results, only the most recent paper was included. Four articles from the search were considered relevant for the therapeutic use of rh[tsh]{.smallcaps} as compared with thyroid hormone withdrawal.

Quality of life was reported in only one of the four selected therapeutic studies [@b15-co16-5-23]. Because [qol]{.smallcaps} was deemed to be an important outcome for the present review, studies evaluating rh[tsh]{.smallcaps} for diagnostic monitoring purposes that otherwise met the inclusion criteria for study design and that reported on [qol]{.smallcaps} were located and reviewed as well. Consequently, the section reporting [qol]{.smallcaps} was supplemented with results from three other studies [@b11-co16-5-23],[@b12-co16-5-23],[@b16-co16-5-23], all of which compared hypothyroid ([hypo]{.smallcaps}) and rh[tsh]{.smallcaps} preparation for the diagnostic use of ^131^ I.

3.2 Study Characteristics
-------------------------

In all four studies of therapeutic use [@b15-co16-5-23],[@b17-co16-5-23]--[@b19-co16-5-23], 0.9 mg of rh[tsh]{.smallcaps} was administered intramuscularly on 2 consecutive days, followed by [ra]{.smallcaps} either 24 [@b15-co16-5-23],[@b17-co16-5-23],[@b19-co16-5-23] or 48 [@b18-co16-5-23] hours after the second dose of rh[tsh]{.smallcaps}. Patients in all four studies had previously undergone total or near-total thyroidectomy. In all of the studies, patients receiving rh[tsh]{.smallcaps} continued on thyroxine replacement throughout their treatment. [Table I](#tI-co16-5-23){ref-type="table"} summarizes the studies.

3.3 Study Quality
-----------------

The literature search only yielded one [rct]{.smallcaps} [@b15-co16-5-23] on the use of rh[tsh]{.smallcaps} therapeutically for [ra]{.smallcaps} preparation. Although of good quality, this study enrolled only 63 participants over a period of 21 months in 9 study sites. However, it is important to note that it was this study that led to the approval of rh[tsh]{.smallcaps} by the European Medicines Agency. In addition, a large prospective trial on this topic is unlikely, given that the incidence of thyroid cancer is too low for a large trial to be feasible in a reasonable amount of time. Furthermore, the favourable prognosis and protracted nature of thyroid cancer means that it takes many years, and even decades, to reach certain endpoints [@b4-co16-5-23].

The cohort studies by Barbaro *et al.* [@b17-co16-5-23] and Pacini *et al.* [@b18-co16-5-23] and the retrospective review by Robbins *et al.* [@b19-co16-5-23] are limited by lack of randomization, making it unclear whether selection bias (either self-selection by patients or selection by physicians) affected the results of a given study. In addition, Barbaro *et al.* [@b17-co16-5-23] used a historical control group (that is, a thyroid hormone withdrawal group), which is methodologically problematic.

3.4 Successful Ablation Rates and Serum Tg Levels
-------------------------------------------------

The [rct]{.smallcaps} reported by Pacini *et al.* [@b15-co16-5-23] compared [ra]{.smallcaps} preparation in 63 patients divided into [hypo]{.smallcaps} and euthyroid (rh[tsh]{.smallcaps}) arms. In this study, a 3700-MBq dose of ^131^I was used. At 8 months' follow-up, 86% of the [hypo]{.smallcaps} group and 75% of the rh[tsh]{.smallcaps} group had a negative [wbs]{.smallcaps} and, as a result, were considered successfully ablated (*p* = 0.3). The rate of successful ablation was 100% in both groups when success was defined as no visible uptake or less than 0.1% ^131^I uptake in the thyroid bed. This definition was reasonable, given that low-grade false positive results occur because of salivary pooling in the oropharynx during the scan. Furthermore, 86% and 83% of the [hypo]{.smallcaps} and rh[tsh]{.smallcaps} groups respectively had serum Tg levels below 1.0 ng/mL ([Table II](#tII-co16-5-23){ref-type="table"}), further indicating that both methods of [ra]{.smallcaps} preparation led to successful ablation rates.

The cohort study reported by Barbaro *et al.* [@b17-co16-5-23] compared [hypo]{.smallcaps} and rh[tsh ra]{.smallcaps} preparation in 93 patients. Notably, patients in the rh[tsh]{.smallcaps} group underwent thyroid hormone withdrawal for 4 days: [l]{.smallcaps}-T4 was discontinued the day before the first dose of rh[tsh]{.smallcaps} and resumed the day after the administration of a 1110- MBq therapeutic dose of ^131^I. The rates of successful ablation were not significantly different between the two groups of patients (*p* value not reported), but at the 1-year follow-up, 75.6% of the [hypo]{.smallcaps} group and 76.9% of the rh[tsh]{.smallcaps} group had a negative [wbs]{.smallcaps}. Serum Tg levels were less than 1.0 ng/mL in 78.0% of the [hypo]{.smallcaps} group and in 86.5% of the rh[tsh]{.smallcaps} group.

Another cohort study, reported by Pacini *et al.* [@b18-co16-5-23], compared [ra]{.smallcaps} preparation in 162 patients. However, in addition to [hypo]{.smallcaps} and rh[tsh]{.smallcaps} groups, a third group was prepared by both thyroid hormone withdrawal and administration of rh[tsh]{.smallcaps} ([hypo]{.smallcaps}+rh[tsh]{.smallcaps}). A 1110-MBq dose of ^131^I was given to all patients in that series. At 6--10 months' follow-up, 84% and 78.5% of patients in the [hypo]{.smallcaps} and [hypo]{.smallcaps}+rh[tsh]{.smallcaps} groups respectively had a negative [wbs]{.smallcaps}, but only 54% (*p* \< 0.0001 and *p* \< 0.01) of those in the rh[tsh]{.smallcaps} group did. It is noteworthy that, in this study, ^131^I was administered 48 hours after the second rh[tsh]{.smallcaps} injection rather than the usual 24 hours, which may have contributed to the lower rate of successful ablation in the rh[tsh]{.smallcaps} arm. However, guidelines published by [ata]{.smallcaps} [@b9-co16-5-23] indicate that serum Tg is the best indicator for successful ablation. They recommended that the uptake and scan procedure be discontinued. Using this criterion, the successful ablation rates were 88%, 95%, and 74.1% in the [hypo]{.smallcaps}, [hypo]{.smallcaps}+rh[tsh]{.smallcaps}, and rh[tsh]{.smallcaps} groups respectively, none of which are significantly different.

Finally, Robbins *et al.* [@b19-co16-5-23] reported retrospectively on a comparison of [hypo]{.smallcaps} and rh[tsh]{.smallcaps} in 87 patients. This study was unique among those reviewed in that the dosage of ^131^I was individually determined based on dosimetry, rather than administered in a standard fixed dose. For both groups, the mean dose was more than 3700 MBq. Follow-up at approximately 1 year post-ablation demonstrated that 80.9% of [hypo]{.smallcaps} and 84.4% of rh[tsh]{.smallcaps} patients had a complete response, defined as complete ablation of all radioiodine uptake in the thyroid bed. In addition, the median serum Tg levels at this follow-up were 0.65 ng/mL and 0.5 ng/mL in the [hypo]{.smallcaps} and rh[tsh]{.smallcaps} groups respectively. Overall, no significant difference was observed between the groups on measures of successful ablation.

3.5 Adverse Events
------------------

Some adverse events were associated with both methods of [ra]{.smallcaps} preparation. Pacini *et al.* [@b15-co16-5-23] reported mild and transient nausea and fatigue in some patients in both groups. Additionally, some patients in the rh[tsh]{.smallcaps} group experienced a loss of taste, and some patients in the [hypo]{.smallcaps} group experienced skeletal pain. Barbaro *et al.* [@b17-co16-5-23] reported observing no significant side effects after the administration of rh[tsh]{.smallcaps}.

3.6 Serum TSH Levels
--------------------

Mean baseline serum [tsh]{.smallcaps} levels in the [hypo]{.smallcaps} patients were significantly higher than those in the rh[tsh]{.smallcaps} groups [@b15-co16-5-23],[@b17-co16-5-23]--[@b19-co16-5-23]. The administration of rh[tsh]{.smallcaps} led to substantial increases in serum [tsh]{.smallcaps} levels from baseline levels in all the studies that reported this variable. Serum [tsh]{.smallcaps} levels are considered sufficient for radioiodine therapy when they reach 25--30 mU/L [@b6-co16-5-23],[@b19-co16-5-23]. [Table III](#tIII-co16-5-23){ref-type="table"} summarizes serum [tsh]{.smallcaps} levels.

3.7 Iodine Biokinetics
----------------------

Baseline 24-hour ^131^I uptake, following administration of a tracer dose of ^131^I, was reported in only two papers. In the Pacini *et al.* [@b18-co16-5-23] report, baseline 24-hour ^131^I uptake in the [hypo]{.smallcaps} and [hypo]{.smallcaps}+rh[tsh]{.smallcaps} groups was 5.8% ± 5.7% and 5.4% ± 5.7% respectively and not significantly different. No baseline value was reported for the rh[tsh]{.smallcaps} group. Following administration of rh[tsh]{.smallcaps}, mean 24-hour ^131^I uptake was 9.4% ± 9.5% in the [hypo]{.smallcaps}+rh[tsh]{.smallcaps} group, which was significantly higher than the baseline level (*p* \< 0.0001), and 2.5% ± 4.3% in the rh[tsh]{.smallcaps} group. The value in the rh[tsh]{.smallcaps} group was significantly lower than that in the [hypo]{.smallcaps}+rh[tsh]{.smallcaps} group (*p* \< 0.0001). Robbins *et al.* [@b19-co16-5-23] reported median baseline 24-hour ^131^I uptake values that were significantly different between the [hypo]{.smallcaps} and rh[tsh]{.smallcaps} groups (1.65% and 0.9% respectively, *p* = 0.05), but did not report values following the administration of rh[tsh]{.smallcaps}. Barbaro *et al.* [@b17-co16-5-23] evaluated 24-hour ^131^I uptake in only a subset of patients after administration of rh[tsh]{.smallcaps}, but found that the [hypo]{.smallcaps} and rh[tsh]{.smallcaps} groups did not differ significantly (3.30% vs. 2.29%). Only two studies reported post-ablation ^131^I uptake [@b15-co16-5-23],[@b19-co16-5-23], and the difference between the [hypo]{.smallcaps} and rh[tsh]{.smallcaps} groups in each study was not statistically significant. [Table IV](#tIV-co16-5-23){ref-type="table"} summarizes 24-hour ^131^I uptake.

Other measures of iodine biokinetics such as mean effective half-life and mean residence time in the remnants are reported only in the paper by Hanscheid *et al.* [@b20-co16-5-23]. The effective half-life is a combination of biologic excretion and physical decay; it is the time after which the ^131^I activity drops by 50%. The effective half-life in remnant tissue was significantly shorter (*p* = 0.01) in the [hypo]{.smallcaps} group than in the euthyroid group (48 ± 52.6 hours vs. 67.6 ± 48.8 hours). Mean residence times in the [hypo]{.smallcaps} and rh[tsh]{.smallcaps} groups were 1.4 ± 1.5 hours and 0.9 ± 1.3 hours respectively (not significantly different). Finally, mean dose to the blood was significantly higher in the [hypo]{.smallcaps} group than in the rh[tsh]{.smallcaps} group (0.167 mGy vs. 0.109 mGy, *p* \< 0.0001). Overall, as compared with patients in the [hypo]{.smallcaps} group, patients in the rh[tsh]{.smallcaps} group received higher doses of radiation to the remnants and a 35% reduction in whole-body radiation dose.

3.8 Quality of Life
-------------------

Baseline [qol]{.smallcaps} in the retrieved studies was taken post cancer diagnosis or post surgery and before initiating a protocol for [tsh]{.smallcaps} elevation. All the studies reviewed for this outcome demonstrated that [qol]{.smallcaps} was worse in the [hypo]{.smallcaps} group when compared with either baseline values or with [qol]{.smallcaps} in the rh[tsh]{.smallcaps} group.

Pacini *et al.* [@b15-co16-5-23] assessed [qol]{.smallcaps} using the Billewicz scale and the Medical Outcomes Study Short Form 36 (SF-36). As compared with participants in the rh[tsh]{.smallcaps} group, participants in the [hypo]{.smallcaps} group scored higher (that is, worse) on 6 of the 14 signs and symptoms of hypothyroidism on the Billewicz scale (*p* \< 0.0001). These items included cold intolerance (50% vs. 21%), weight gain (60% vs. 21%), constipation (43% vs. 3%), slow movements (50% vs. 12%), cold skin (47% vs. 12%), and peri-orbital puffiness (50% vs. 0%). In addition, the change from baseline to week 4 in the euthyroid group was significantly different from the change observed in the [hypo]{.smallcaps} group for 5 of the 8 health-related [qol]{.smallcaps} domains of the SF-36. These domains were physical functioning (*p* \< 0.016), role-physical (*p* \< 0.018), vitality (*p* \< 0.0001), social functioning (*p* \< 0.0001), and mental health (*p* \< 0.002).

Schroeder *et al.* [@b12-co16-5-23] expressly set out to assess and compare [qol]{.smallcaps} in patients undergoing preparation for diagnostic evaluation using [tsh]{.smallcaps} withdrawal and rh[tsh]{.smallcaps}. Those authors determined that, for all 14 signs and symptoms of hypothyroidism on the Billewicz scale, [qol]{.smallcaps} was significantly worse in the [hypo]{.smallcaps} group than in the rh[tsh]{.smallcaps} group (*p* \< 0.001). Likewise, they found that, as compared with patients in the rh[tsh]{.smallcaps} group, patients in the [hypo]{.smallcaps} group reported significantly lower [qol]{.smallcaps} on all 8 health-related [qol]{.smallcaps} domains on the SF-36 (*p* \< 0.0001) and on the physical and mental composite scores of the SF-36 (*p* \< 0.0001 in each case). Ladenson *et al.* [@b11-co16-5-23] also found that [qol]{.smallcaps} was significantly worse in the [hypo]{.smallcaps} group as compared with the rh[tsh]{.smallcaps} group on all signs and symptoms of hypothyroidism on the Billewicz scale (*p* \< 0.001). This group of researchers also assessed [qol]{.smallcaps} using the Profile of Mood States ([poms]{.smallcaps}) and reported that, as compared with the euthyroid group, the [hypo]{.smallcaps} group had significantly worse [qol]{.smallcaps} on all 6 states measured on the [poms]{.smallcaps} (*p* \< 0.001). Finally, in 2002, Ladenson [@b16-co16-5-23] compared [qol]{.smallcaps} in [hypo]{.smallcaps} and rh[tsh]{.smallcaps} groups and found that the [hypo]{.smallcaps} group had significantly worse [qol]{.smallcaps} for 5 of the 6 states assessed on the [poms]{.smallcaps} and for the physical composite scores of the SF-36, although probability values were not reported in that article.

3.9 Cost Effectiveness
----------------------

Three studies investigated the economic impact of rh[tsh]{.smallcaps} as compared with hormone withdrawal.

Luster *et al.* [@b21-co16-5-23] conducted a retrospective survey. Of patients who were employed in salaried positions outside the home, 62% missed at least 4 days of work (median: 11 days) during their last hypothyroid episode. When outliers were removed from the data, the median number of days missed was still 7.5 (range: 0--70 days). Moreover, 38% of respondents reported taking additional prescription or over-the-counter drugs to relieve hypothyroid symptoms, and 48% reported the use of a primary care physician, a specialist physician, or hospital services because of hypothyroid symptoms. In the economic model presented in the article, the societal cost per diagnostic [wbs]{.smallcaps} with preparation by thyroid hormone withdrawal exceeded by 25% or €326 that with preparation by rh[tsh]{.smallcaps} [@b21-co16-5-23].

Borget *et al.* [@b22-co16-5-23] compared the frequency, duration, and cost of sick leave for follow-up of thyroid cancer in hormone-withdrawal and rh[tsh]{.smallcaps} patients. Active patients in the rh[tsh]{.smallcaps} arm were less likely to need sick leave than were those in the [hypo]{.smallcaps} arm (11% vs. 33%, *p* = 0.001), and they had shorter sick leaves (3.1 days vs. 11.2 days, *p* = 0.002). Indirect costs owing to absenteeism amounted to €1083 more per person in the [hypo]{.smallcaps} group than in the rh[tsh]{.smallcaps} group.

Mernagh *et al.* [@b23-co16-5-23] conducted a cost-effectiveness evaluation of rh[tsh]{.smallcaps} compared with hormone withdrawal and reported that the benefits of rh[tsh]{.smallcaps} are achieved with a small incremental societal cost of €47. That difference equates to an incremental cost-effectiveness ratio of €950 per quality-adjusted life year, which is considered to be very good value for money, considering that new health care interventions are deemed cost-effective if their incremental cost-effectiveness ratio falls below €45,000 [@b23-co16-5-23].

4. DISCUSSION
=============

There are two fundamental reasons to administer ^131^I following thyroidectomy for differentiated thyroid cancer---namely,

-   as adjuvant therapy to destroy the remaining normal thyroid follicular cells to facilitate follow-up and to ease early detection of recurrence, or

-   as therapy for disease that proved to be unresectable at surgery.

This review has been concerned only with the first of these indications. Because ablation is directed against residual normal thyroid cells, the specifics of the underlying differentiated malignancy are not relevant to this discussion. Here, we compared only the methods of elevating [tsh]{.smallcaps} against the endpoint of successful ablation; we did not address ongoing debates concerning other aspects of thyroid cancer care.

A systematic review of the available evidence on the use of rh[tsh]{.smallcaps} compared with thyroid hormone withdrawal in preparation for [ra]{.smallcaps} yielded four relevant studies consisting of one [rct]{.smallcaps}, two cohort studies, and one retrospective study. Examination of the outcomes of these studies with respect to achieving ablation revealed that the use of rh[tsh]{.smallcaps} for [ra]{.smallcaps} preparation is not different from thyroid hormone withdrawal. Three of these four studies found similar rates of negative [wbs]{.smallcaps} by both methods of preparation [@b15-co16-5-23],[@b17-co16-5-23],[@b19-co16-5-23]. Following surgery and [ra]{.smallcaps}, [tsh]{.smallcaps}-stimulated serum Tg under either method of preparation is a sensitive indicator of residual thyroid tissue or the presence of cancer (or both). By the criteria of negative [wbs]{.smallcaps} and Tg, hypothyroid and euthyroid patients in all four studies had similar rates of successful ablation at 6--12 months post-ablation follow-up [@b15-co16-5-23],[@b17-co16-5-23]--[@b19-co16-5-23].

Serum [tsh]{.smallcaps} levels of 25--30 mU/L are considered sufficiently high for radioiodine therapy [@b6-co16-5-23],[@b19-co16-5-23]. In all the studies reviewed, serum [tsh]{.smallcaps} in the hypothyroid patients was sufficient to ensure an adequate uptake of ^131^I. Three studies reported that serum [tsh]{.smallcaps} levels after administration of rh[tsh]{.smallcaps} were sufficient for the ^131^I uptake needed for [ra]{.smallcaps} therapy. Successful ablation was defined by some researchers as a 24-hour ^131^I uptake in the thyroid bed of less than 1% of the administered dose in a follow-up scan [@b24-co16-5-23]. Of the two studies reporting that endpoint [@b15-co16-5-23],[@b19-co16-5-23], both found 24- hour ^131^I uptake to be less than 1%, with no significant difference between patients prepared by thyroid withdrawal and patients prepared by rh[tsh]{.smallcaps}.

In two studies [@b18-co16-5-23],[@b25-co16-5-23], a fixed 1110-MBq dose of ^131^I was administered to all patients, but in a more recent study [@b15-co16-5-23], a larger fixed 3700-MBq dose was used. In the Robbins *et al.* [@b19-co16-5-23] study, the ^131^I administered to each individual patient was calculated based on dosimetry. The mean dose in both groups in that study was well above 3700-MBq. The higher dose of ^131^I might result in higher successful ablation rates. Centres continue to differ in the selection of ^131^I dosage, but these differences did not affect our review of the methods employed to elevate [tsh]{.smallcaps}.

The report by Hanscheid *et al.* [@b20-co16-5-23] regarding other biokinetic measures in the patients originally studied by Pacini *et al.* [@b15-co16-5-23] found that the mean radiation dose in the remnant was similar in the two groups, but that the mean blood dose, a proxy for whole-body dose, was significantly (30%) lower. That difference is attributable to the impairment of renal function that occurs during hypothyroidism [@b20-co16-5-23].

Investigators continue to explore the limits of safe and effective ^131^I dosage. In a recent [rct]{.smallcaps}, Pilli *et al.* [@b26-co16-5-23] compared 1850-MBq and 3700-MBq doses of ^131^I after preparation by rh[tsh]{.smallcaps} and demonstrated the same rate of successful ablation (88.9%) in each arm. At the high end of the dose range, Tuttle *et al.* [@b27-co16-5-23] conducted a retrospective analysis of 535 dosimetry studies in [hypo]{.smallcaps} patients and concluded that the fixed empiric dosing strategy of 5550--9250 MBq used by many centres frequently results in older patients (70 years of age and older) being exposed to a blood radiation dose of more than 200 cGy, the recommended safety limit. A lower body radiation dose achieved through preparation with rh[tsh]{.smallcaps} may lower the risk of radiation-induced second cancers [@b28-co16-5-23], although this effect has not been confirmed in trials. Collectively, the foregoing studies make a compelling argument in favour of rh[tsh]{.smallcaps} preparation for [ra]{.smallcaps} ablation.

The studies measuring [qol]{.smallcaps} [@b11-co16-5-23],[@b12-co16-5-23],[@b15-co16-5-23],[@b16-co16-5-23] consistently reported improved [qol]{.smallcaps} in terms of both hypothyroid symptoms and general quality of life for rh[tsh]{.smallcaps} as compared with [hypo]{.smallcaps} on the Billewicz, SF-36, and [poms]{.smallcaps} instruments.

The direct cost of [ra]{.smallcaps} by either protocol is identical, except that rh[tsh]{.smallcaps} costs \$1500 in Canada. The previously cited European studies of cost-effectiveness showed that rh[tsh]{.smallcaps}-treated patients had a better [qol]{.smallcaps} and, as a result of improved performance capacity, were returning earlier to work and making less use of the health care system. These benefits likely translate to the Canadian environment as well.

Finally, some patients cannot achieve satisfactory levels of endogenous [tsh]{.smallcaps} with thyroid hormone withdrawal, and others are contraindicated for hypothyroidism because of other medical disorders. Studies in these populations demonstrated that the use of rh[tsh]{.smallcaps} is effective [@b29-co16-5-23],[@b30-co16-5-23].

Prospective [rct]{.smallcaps}s investigating the therapeutic use of rh[tsh]{.smallcaps} are limited in number. Other prospective and retrospective studies have the potential biases inherent in nonrandomized data. However, it is compelling that all the studies retrieved for this review demonstrated the consistent efficacy of rh[tsh]{.smallcaps} as a preparation method for [ra]{.smallcaps} of thyroid remnants.

The indolence of differentiated thyroid cancers complicates the understanding of long-term outcomes following ablation by whatever protocol. Two recent reports considered the long-term efficacy of ablation therapy given with rh[tsh]{.smallcaps} stimulation: one was a follow-up of the Pacini *et al.* series at 3 years [@b31-co16-5-23], and the other was a retrospective review of outcomes in 176 patients at 3--8.5 years later [@b32-co16-5-23]. In both cases, no differences were found.

5. CONCLUSIONS
==============

Based on current evidence, the efficacy of rh[tsh]{.smallcaps} for [ra]{.smallcaps} preparation following total or near-total thyroidectomy in patients with papillary or follicular thyroid cancer is equivalent to the traditional method of thyroid hormone withdrawal. In selected patients who cannot tolerate prolonged hypothyroidism or in patients who cannot achieve satisfactory elevation of endogenous [tsh]{.smallcaps} by means of thyroid hormone withdrawal, rh[tsh]{.smallcaps} may be the only option for radioablation. Recombinant humanized [tsh]{.smallcaps} allows patients to remain euthyroid, thereby avoiding the morbidities of hypothyroidism and resulting in better [qol]{.smallcaps} than is seen with thyroid hormone withdrawal.
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###### 

Summary of studies in the literature

  Reference                                Study type                    Comparison                          Patients   Thyroid cancer type   Thyroidectomy type                                                                                                     
  ---------------------------------------- ----------------------------- ----------------------------------- ---------- --------------------- -------------------- ---------------------------------------------------- -------------------------------------------- ---------------------
  Pacini *et al.,* 2002[@b18-co16-5-23]    Cohort                        Hypothyroid                         50         36                    14                   17--75                                               Papillary or follicular                      Total or near-total
                                                                         Hypothyroid + rh[tsh]{.smallcaps}   42         30                    12                                                                                                                     
                                                                         rh[tsh]{.smallcaps}                 70         53                    17                                                                                                                     
  Robbins *et al.,* 2002[@b19-co16-5-23]   Retrospective                 Hypothyroid                         42         17                    25                   42.2±17.5                                            Papillary                                    Total or near-total
                                                                         rh[tsh]{.smallcaps}                 45         27                    18                   49.9±13.3[a](#tfn2-co16-5-23){ref-type="table-fn"}                                                
  Barbaro *et al.,* 2006[@b17-co16-5-23]   Cohort                        Hypothyroid                         41         26                    15                   19--71                                               Papillary or minimally invasive follicular   Total
                                                                         rh[tsh]{.smallcaps}                 52         35                    17                                                                                                                     
  Pacini *et al.,* 2006[@b15-co16-5-23]    Randomized controlled trial   Hypothyroid                         30         24                    6                    20--68                                               Papillary or follicular                      Total or near-total
                                           rh[tsh]{.smallcaps}           33                                  26         7                                                                                                                                            

rh[tsh]{.smallcaps} = recombinant humanized thyroid-stimulating hormone.

*p*\<0.05.

###### 

Rates of successful ablation and levels of serum thyroglobulin (Tg), by study

  Reference                                Comparison                          ^131^I Dose                                                   Successful ablation (negative [wbs]{.smallcaps}) (%)          Serum Tg \< 1 ng/mL at 6--12 months' follow-up (%)
  ---------------------------------------- ----------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- -----------------------------------------------------
  Pacini *et al.,* 2002[@b18-co16-5-23]    Hypothyroid                         1110 MBq                                                      84.0 (*p*\<0.0001)[a](#tfn3-co16-5-23){ref-type="table-fn"}   83.3[b](#tfn4-co16-5-23){ref-type="table-fn"}
                                           Hypothyroid + rh[tsh]{.smallcaps}                                                                 78.5 (*p*\<0.01)[a](#tfn3-co16-5-23){ref-type="table-fn"}     84.8[b](#tfn4-co16-5-23){ref-type="table-fn"}
                                           rh[tsh]{.smallcaps}                                                                               54.0                                                          86.8[b](#tfn4-co16-5-23){ref-type="table-fn"}
  Robbins *et al.,* 2002[@b19-co16-5-23]   Hypothyroid                         Based on dosimetry[c](#tfn5-co16-5-23){ref-type="table-fn"}   80.9                                                          0.65 ng/mL[d](#tfn6-co16-5-23){ref-type="table-fn"}
                                           rh[tsh]{.smallcaps}                                                                               84.4                                                          0.50 ng/mL[d](#tfn6-co16-5-23){ref-type="table-fn"}
  Barbaro *et al.*, 2006[@b17-co16-5-23]   Hypothyroid                         1110 MBq                                                      75.6                                                          78.0
                                           rh[tsh]{.smallcaps}                                                                               76.9                                                          86.5
  Pacini *et al.,* 2006[@b15-co16-5-23]    Hypothyroid                         3700 MBq                                                      86.0                                                          86.0
                                           rh[tsh]{.smallcaps}                                                                               75.0                                                          83.0

Compared with rh[tsh]{.smallcaps} alone.

Based on patients whose ablation was successful.

Mean ± standard deviation dose was 4769.3 ± 2738 MBq and 4084.8 ± 2405 MBq for the hypothyroid and rh[tsh]{.smallcaps} groups respectively.

Median Tg level.

[wbs]{.smallcaps} = whole-body scan; rh[tsh]{.smallcaps} = recombinant humanized thyroid-stimulating hormone.

###### 

Serum levels of thyroid-stimulating hormone ([tsh]{.smallcaps})

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                Comparison                          Mean serum [tsh]{.smallcaps} ± standard deviation (mU/L)   
  ---------------------------------------- ----------------------------------- ---------------------------------------------------------- ----------------------------------------------------
  Pacini *et al.,* 2002[@b18-co16-5-23]    Hypothyroid                         63.2±19.6[a](#tfn8-co16-5-23){ref-type="table-fn"}         [na]{.smallcaps}

                                           Hypothyroid + rh[tsh]{.smallcaps}   71.0±35.9[a](#tfn8-co16-5-23){ref-type="table-fn"}         281±97.0[a](#tfn8-co16-5-23){ref-type="table-fn"}\
                                                                                                                                          (*p*\<0.0001)

                                           rh[tsh]{.smallcaps}                 1.30±2.5[a](#tfn8-co16-5-23){ref-type="table-fn"}\         126±44.8[a](#tfn8-co16-5-23){ref-type="table-fn"}\
                                                                               (*p*\<0.0001)                                              (*p*\<0.0001)

  Robbins *et al.,* 2002[@b19-co16-5-23]   Hypothyroid                         97.5±50                                                    [na]{.smallcaps}

                                           rh[tsh]{.smallcaps}                 6.0±9.5                                                    105.1±45.4

  Barbaro *et al.,* 2006[@b17-co16-5-23]   Hypothyroid                         50±3                                                       [na]{.smallcaps}

                                           rh[tsh]{.smallcaps}                 0.04--0.35[b](#tfn9-co16-5-23){ref-type="table-fn"}        126±10

  Pacini *et al.,* 2006[@b15-co16-5-23]    Hypothyroid                         83.0±51                                                    [na]{.smallcaps}

                                           rh[tsh]{.smallcaps}                 1.1±1.3                                                    [nr]{.smallcaps}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pacini *et al.* (2002)[@b18-co16-5-23] report serum [tsh]{.smallcaps} levels in microunits per millilitre, which is equivalent to milliunits per litre.

Range reported only.

rh[tsh]{.smallcaps} = recombinant humanized [tsh; na]{.smallcaps} = not applicable; [nr]{.smallcaps} = not reported.

###### 

Iodine biokinetics in remnants: 24-hour ^131^I uptake (mean ± standard deviation)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                Comparison                          Before rh[tsh]{.smallcaps}                       24-Hour ^131^I uptake Hypothyroid or after rh[tsh]{.smallcaps}   After ablation
  ---------------------------------------- ----------------------------------- ------------------------------------------------ ---------------------------------------------------------------- ---------------------------------------------------
  Pacini *et al.,* 2002[@b18-co16-5-23]    Hypothyroid                         5.8±5.7                                          [na]{.smallcaps}                                                 [nr]{.smallcaps}

                                           Hypothyroid + rh[tsh]{.smallcaps}   5.4±5.7                                          9.4±9.5\                                                         [nr]{.smallcaps}
                                                                                                                                (*p*\<0.0001)[a](#tfn11-co16-5-23){ref-type="table-fn"}          

                                           rh[tsh]{.smallcaps}                 [nr]{.smallcaps}                                 2.5±4.3\                                                         [nr]{.smallcaps}
                                                                                                                                (*p*\<0.0001)[b](#tfn12-co16-5-23){ref-type="table-fn"}          

  Robbins *et al.,* 2002[@b19-co16-5-23]   Hypothyroid                         1.65[c](#tfn13-co16-5-23){ref-type="table-fn"}   [na]{.smallcaps}                                                 0.25[c](#tfn13-co16-5-23){ref-type="table-fn"}

                                           rh[tsh]{.smallcaps}                 0.9[c](#tfn13-co16-5-23){ref-type="table-fn"}\   [nr]{.smallcaps}                                                 0.17[c](#tfn13-co16-5-23){ref-type="table-fn"}
                                                                               (*p*=0.05)                                                                                                        

  Barbaro *et al.,* 2006[@b17-co16-5-23]   Hypothyroid                         [nr]{.smallcaps}                                 3.30±0.7[d](#tfn14-co16-5-23){ref-type="table-fn"}               [nr]{.smallcaps}

                                           rh[tsh]{.smallcaps}                 [nr]{.smallcaps}                                 2.29±0.45[d](#tfn14-co16-5-23){ref-type="table-fn"}              [nr]{.smallcaps}

  Pacini *et al.,* 2006[@b15-co16-5-23]    Hypothyroid                         [nr]{.smallcaps}                                 [na]{.smallcaps}                                                 0.9±1.1[e](#tfn15-co16-5-23){ref-type="table-fn"}

                                           rh[tsh]{.smallcaps}                 [nr]{.smallcaps}                                 [nr]{.smallcaps}                                                 0.5±0.7[e](#tfn15-co16-5-23){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comparison within the hypothyroid + rh[tsh]{.smallcaps} group, before and after rh[tsh]{.smallcaps}.

Comparison between the hypothyroid + rh[tsh]{.smallcaps} group and the rh[tsh]{.smallcaps} group after rh[tsh]{.smallcaps}.

Median value.

Evaluated on a subset of patients only.

48-Hour ^131^I uptake.

rh[tsh]{.smallcaps} = recombinant humanized [tsh; nr]{.smallcaps} = not reported; [na]{.smallcaps} = not applicable.
